Please login to the form below

Not currently logged in
Email:
Password:

NASH

This page shows the latest NASH news and features for those working in and with pharma, biotech and healthcare.

Gilead and Novo Nordisk boost NASH partnership with new mid-stage study

Gilead and Novo Nordisk boost NASH partnership with new mid-stage study

NASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver, which can lead to scarring, or fibrosis, that impairs liver function. ... If left untreated, individuals living with NASH may face serious

Latest news

  • Merck enters agreement with Hanmi for investigational NASH drug Merck enters agreement with Hanmi for investigational NASH drug

    The deal with Hanmi builds on Merck’s existing NASH pipeline, which includes a mid-stage candidate, NGM313, licensed from NGM Biopharmaceuticals last year. ... NGM313 is an antibody targeting the beta-Klotho/FGFR1c receptor complex that could represent

  • Genfit scraps phase 3 trial of experimental NASH drug Genfit scraps phase 3 trial of experimental NASH drug

    Drug failed to meet primary endpoint in interim analysis. Genfit has put the brakes on a late-stage trial of its experimental nonalcoholic steatohepatitis (NASH) drug elafibranor after reporting disappointing results ... The phase 3 RESOLVE-IT trial was

  • Bayer signs €250m pact with India’s Curadev for STING drugs Bayer signs €250m pact with India’s Curadev for STING drugs

    Excessive signalling through cGAS–STING has been linked to a range of chronic and rare diseases, including neurodegenerative conditions like Parkinson’s, pulmonary fibrosis and non-alcoholic steatohepatitis (NASH).

  • Zydus Cadila scores first ever NASH approval, in India Zydus Cadila scores first ever NASH approval, in India

    Saroglitazar will provide hope and new lease of life for millions of patients in India suffering from NASH,” he added. ... Another potential treatment for NASH – from Intercept – is currently under review with the US Food and Drug Administration

  • FDA delays decision on Intercept's NASH drug by three months FDA delays decision on Intercept's NASH drug by three months

    As it stands, Intercept is poised to access the NASH market before its larger rivals but it is unclear if that first-mover advantage will translate into commercial success. ... Diagnosis is another potential barrier to sales growth. NASH is definitively

More from news
Approximately 31 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • Keeping up the fight against HIV and using the lessons to tackle other threats Keeping up the fight against HIV and using the lessons to tackle other threats

    Gilead, which has suffered two recent NASH therapy trial knock-backs, believes medical and scientific advances need to be welded to comprehensive patient engagement to engineer effective responses to what is ... being labelled as the next public health

  • Deal Watch October 2018

    treatments for NASH with Pfizer products. Not. disclosed. One of the big deals for Novartis these last two months was the long‐rumoured sale of it’s Sandoz division’s US ... The agreement is driven by the belief that liver diseases will respond

  • Taking a lean and careful approach Taking a lean and careful approach

    A lot of NASH patients also have these conditions so we want to look at and understand the underlying causes to see what else we can come up with there.”. ... The NASH market is expected to be worth $20bm by 2025 and financial brokers recently valued

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Oncology, immuno-oncology and central nervous system therapies once again topped the charts, but 2016 also saw the emergence of new areas, notably non-alcoholic steatohepatitis or NASH. ... With NASH appearing to be a long-term consequence of obesity it

  • Deal Watch December 2016 Deal Watch December 2016

    The Scandinavian company, Nuevolution, uses its drug discovery platform Chemetics to discover novel small molecules in the field of chronic inflammatory diseases, including psoriasis, rheumatoid arthritis, non-alcoholic steato-hepatitis (NASH),

More from intelligence
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....